
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics Inc. is witnessing promising advancements in its fibroblast-based therapies, particularly in preclinical settings for chronic-relapse psoriasis and bone marrow organoids aimed at cancer treatments, highlighting the potential versatility and marketability of its technology. The company is strategically improving its operational efficiency while investing in research and development, evidenced by a nine-month R&D expenditure of $6.6 million, which reflects its commitment to scaling up for clinical use and increasing manufacturing capabilities. Additionally, the broad intellectual property portfolio and focus on chronic diseases with unmet needs support a potentially advantageous position in lowering production costs and overcoming regulatory challenges, thereby enhancing the overall outlook for the company's financial future.
Bears say
FibroBiologics faces significant challenges impacting its financial outlook, including the risk of its developmental candidates failing to meet commercial revenue expectations due to market dynamics and pricing pressures. The company reported a net loss of $5.8 million for the third quarter of 2025, contributing to an over 80% decline in stock value year-to-date, contrasting sharply with a 20% increase in the Nasdaq Biotechnology Index. Additionally, rising research and development costs, driven by increased spending on CRO, cell manufacturing, and personnel, have further widened the company's losses despite efforts to implement cost efficiencies.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares